Table 2.
Serum HA means standard deviation at different study times and treatment groups.
| Study time | CT | PRGF | AMSCs | PRGF + AMSCs |
|---|---|---|---|---|
| Baseline | 635.67 ± 76.64 | 625.18 ± 114.26 | 513.87 ± 174.65 | 592.13 ± 86.57 |
| 28 days post-infiltration | 1,319.04 ± 524.36 | 1,767.22 ± 936.37 | 1,513.78 ± 716.37 | 1,408.60 ± 533.21 |
| 56 days post-infiltration | 1,234.96 ± 391.67 | 770.99 ± 104.67 | 804.99 ± 50.21 | 757.93 ± 46.12 |
| 84 days post-infiltration | 1,333.54 ± 265.19 | 821.90 ± 43.29 | 826.92 ± 59.66 | 610.05 ± 64.44 |
CT, control; PRGF, plasma rich in growth factors; AMSCs, adipose mesenchymal stromal cells; PRGF + AMSCs, combination of plasma rich in growth factors with adipose mesenchymal stromal cells.